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We report the first case of nonimmune hydrops fetalis (NIHF) associated with a recessive, in-frame deletion of V205 in 
the G protein–coupled receptor, Calcitonin Receptor-Like Receptor (hCAL CRL). Homozygosity results in fetal demise from 
hydrops fetalis, while heterozygosity in females is associated with spontaneous miscarriage and subfertility. Using molecular 
dynamic modeling and in vitro biochemical assays, we show that the hCLR(V205del) mutant results in misfolding of the first 
extracellular loop, reducing association with its requisite receptor chaperone, receptor activity modifying protein (RAMP), 
translocation to the plasma membrane and signaling. Using three independent genetic mouse models we establish that 
the adrenomedullin–CLR–RAMP2 axis is both necessary and sufficient for driving lymphatic vascular proliferation. Genetic 
ablation of either lymphatic endothelial Calcrl or nonendothelial Ramp2 leads to severe NIHF with embryonic demise and 
placental pathologies, similar to that observed in humans. Our results highlight a novel candidate gene for human congenital 
NIHF and provide structure–function insights of this signaling axis for human physiology.
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Introduction
In early stages of intrauterine development, changes in fluid 
distribution and equilibrium are not well tolerated (Brace, 1989; 
Brace and Valenzuela, 1990). Impaired lymphatic drainage in 
adults often presents with chronic swelling or lymphedema, but 
in the fetus it can develop into a more severe and lethal con-
dition known as hydrops fetalis (HF; Apkon, 1995; Bukowski 
and Saade, 2000; Randenberg, 2010a,b). The term HF refers to 
excessive fluid accumulation in more than two fetal extra vas-
cular compartments and body cavities and is characterized by 
generalized skin thickness of >5 mm, placental enlargement 
and edema, pericardial or pleural effusion, or ascites (Bellini 
et al., 2009, 2015; Bellini and Hennekam, 2012). HF is further 
subdivided into two categories, Rhesus iso-immunization or 
immune HF, which is common in developing countries, and 
nonimmune HF (NIHF). In Westernized countries, effective 
Rhesus (Rh) alloimmunization during pregnancy has reduced 
the number immune related HF cases to <10%, such that NIHF 
now accounts for 85–90% of all hydrops cases. The etiology of 
NIHF is further subdivided into 14 classification groups based 
on the cause of the disorder (Randenberg, 2010a,b). Within 
these subgroups, generalized lymphatic dysplasia (GLD) is the 
third leading cause of NIHF, following cardiovascular and id-
iopathic disorders, the latter of which account for 20% of all 
known NIHF cases.
In an attempt to understand the underlying causes of NIHF, 
Connell et al. developed a new classification system as a clinical 
and research tool to further delineate primary lymphedema con-
ditions and facilitate the identification of new causative genes 
linked to GLD (Connell et al., 2013). Hennekam Syndrome (OMIM 
no. 235510) was the first inherited form of GLD described and is 
caused by loss-of-function mutations in the collagen and calcium 
binding EGF domains 1 (CCBE1) gene in an autosomal recessive 
manner (Alders et al., 2009; Connell et al., 2010). Consistent with 
the prevalent role of the CCBE1–VEGF-C–VEG FR3 signaling axis 
in lymphangiogenesis, genes encoding modifiers of this pathway 
have also been described in a limited number of families with 
Hennekam syndrome, such as atypical cadherin 4, FAT4 (Alders 
et al., 2014), and ADAM metallopeptidase with thrombospondin 
motif, ADA MTS3 (Brouillard et al., 2017). More recently, biallelic 
mutations in piezo-type mechanosensitive ion channel compo-
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nent 1 (PIE ZO1) and heterozygous inactivating mutations in the 
Eph receptor B4 (EPHB4) have also been identified as causative 
of GLD in humans (Fotiou et al., 2015; Lukacs et al., 2015; Martin-
Almedina et al., 2016). These new discoveries suggest that GLD is 
genetically heterogeneous and provides precedent for the iden-
tification of novel genetic pathways.
Calcitonin receptor-like receptor (CAL CRL, gene; CLR, pro-
tein) is a G protein–coupled receptor (GPCR) that forms an active 
signaling complex for either adrenomedullin (AM) peptide or 
calcitonin gene related peptide (CGRP), depending on the re-
ceptor’s interaction with a family of receptor activity-modifying 
proteins (RAMPs 1–3) (McLatchie et al., 1998; Kamitani et al., 
1999; Hay et al., 2006; Woolley and Conner, 2013). Coexpression 
and direct protein–protein interaction of a RAMP with CLR is 
required for their forward translocation from the cytoplasm to 
the plasma membrane. Moreover, the RAMP moiety also deter-
mines ligand binding specificity, such that an interaction be-
tween CLR and RAMP2 or RAMP3 leads to the formation of a 
receptor complex that preferentially binds AM (AM1 and AM2 
receptors, respectively), while a CLR–RAMP1 complex creates 
the active form of the CGRP-binding receptor. Selective an-
tagonists and neutralizing antibodies that exploit this unique 
paradigm of GPCR selectivity and function have very recently 
shown great promise in phase III clinical trials for the therapeu-
tic treatment of migraine (Goadsby et al., 2017; Silberstein et al., 
2017). Yet, there are currently no known conditions or diseases 
associated with loss-of-function of these genes and signaling 
pathways in humans.
We and others have used genetic approaches in mice to elu-
cidate the developmental and physiological functions of this 
complex GPCR signaling pathway in vivo (Kamitani et al., 1999; 
Dackor et al., 2006; Fritz-Six et al., 2008; Ichikawa-Shindo et al., 
2008; Kadmiel et al., 2011; Koyama et al., 2013). Although genetic 
loss of murine Ramp1, Ramp3, or CalcA/B is compatible with 
long-term survival (Dackor et al., 2007), global deletion of the 
genes encoding either AM, CLR, or RAMP2 results in embryonic 
lethality at mid-gestation characterized by marked HF caused 
by a developmental arrest of lymphangiogenesis (Caron and 
Smithies, 2001; Dackor et al., 2006, 2007; Fritz-Six et al., 2008; 
Ichikawa-Shindo et al., 2008). Additionally, female mice that are 
haploinsufficient for Adm, Calcrl, or Ramp2 exhibit significant 
subfertility associated with abnormal uterine receptivity, pla-
cental defects and fetal growth restriction, which are maternally 
linked phenotypes largely independent of the genotype of the 
fetus (Li et al., 2006, 2008).
Here, we identify a novel recessive form of GLD that presents 
with NIHF and fetal demise in the homozygous state, as well as 
accompanying clinical subfertility in women heterozygous for a 
loss-of-function mutation in the CAL CRL gene. Using molecular 
dynamic modeling, newly developed biochemistry approaches, 
and in vivo conditional genetic models, we further reveal that the 
in-frame deletion variant in the CAL CRL gene reduces the trans-
location of the active CLR–RAMP receptor complex to the plasma 
membrane, resulting in decreased receptor function, which in 
complementary genetic mouse models, underscores the cell au-
tonomous requirement of the CLR–RAMP2–AM signaling axis 
within lymphatic endothelial cells.
Results
Clinical assessment of a family presenting with subfertility 
and hydropic fetuses
The proband, a 22-yr-old asymptomatic woman G4 P1211 (Fig. 1 A, 
III.4), with normal liver enzymes and no signs of diabetes mel-
litus or hypertension, was referred to the genetics clinic after 
experiencing three pregnancies resulting in intrauterine fetal 
demise. Her first pregnancy resulted in a healthy baby girl (IV.1). 
The second pregnancy (Fig. 1 A, IV.2) was complicated by HF and 
mild polyhydramnios, which were noticed during second trimes-
ter ultrasounds. The first ultrasound during the 22nd week of 
gestation was inconclusive due to fetal positioning. However, the 
second ultrasound during the 27th week of gestation (26 wk + 3 
d), which exhibited normal radiological parameters, confirmed 
the presence of HF, with a biparietal diameter measurement 
equivalent to 40 wk + 5 d and a head circumference equivalent 
to 33 wk + 6 d. Consistent with the diagnostic criteria for HF 
(Apkon, 1995; Bellini et al., 2006, 2009; Bellini and Hennekam, 
2012), significant interstitial fluid was noted in more than two 
extravascular compartments, including marked pleural effusion 
indicated by reduced lung size, marked skin edema, and pericar-
dial effusion. The pericardial effusion was also associated with 
impaired cardiac outflow. The pregnancy continued to 29 wk, 
after which the fetal movement completely ceased.
During the proband’s third pregnancy (Fig.  1  A, IV.3), two 
ultrasounds were performed in the clinic. The first was at 12 
wk of gestation and was determined to be normal. The second 
was at 21 wk and showed normal cardiac outflow with no major 
anomalies. However, at 22 wk of gestation, the proband noted 
poor intrauterine movements, and an ultrasound revealed mild 
polyhydramnios with significant presentation of HF. Due to the 
previous history of intrauterine fetal demise, blood was collected 
from the fetus for genetic testing.
The proband’s fourth pregnancy (Fig.  1 A, IV.4) resulted in 
spontaneous miscarriage at 8 wk of gestation when she pre-
sented with sudden onset of vaginal bleeding. No fetal or pla-
cental tissue was obtained from IV.4.
Placental pathology consistent with HF
Placental pathology was performed on IV.2 and IV.3 with find-
ings consistent with the clinical presentation of HF. The umbil-
ical cord of IV.2 appeared normal, with a trivascular structure 
consisting of two arteries and one vein. In addition, the fetal 
membranes were translucent and negative for acute chorioam-
nionitis. However, the singleton aborted placenta was edematous 
and large for the gestational age, weighing 1,113 g. Compared with 
an unaffected, gestationally matched, 24-wk placenta (Fig. 1 B, 
top panels), the placenta of IV.2 showed diffuse edematous cho-
rionic villi, with severe villus edema and scattered Hofbauer cells 
(Fig. 1 B, middle panels). Furthermore, the fetal vessels appeared 
abnormally shaped and compressed, likely due to the encroach-
ing villus edema.
Similar to IV.2, the IV.3 singleton placenta was large for ges-
tation age, weighing 484 g. The umbilical cord was trivascular 
with no noticeable acute arteritis or phlebitis. The placenta was 
negative for villitis and viral cytopathic effects, with translucent 
membranes negative for acute chorioamnionitis. However, his-
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topathological evaluation revealed edematous chorionic villi, an 
increased number of Hofbaeur cells and chorangiosis (Fig. 1 B, 
bottom panels). Once again, some of the fetal vessels appeared 
multi-lobular in shape and compressed to the outer rims of the 
chorionic villi, likely due to encroaching villus edema. Collec-
tively, these placental findings are consistent with the fetal pre-
sentation of NIHF.
Exome sequencing to identify causal CAL CRL (V205del) variant
The family history of consanguinity (Fig. 1 A) indicated that the 
fetal demise and resulting subfertility could be related to a ho-
mozygous variant. To address this hypothesis, exome sequenc-
ing was performed on blood samples collected from III.4, III.3, 
and IV.3. We first searched for potentially damaging variants in 
known genes recently implicated with NIHF with GLD, includ-
ing PIE ZO1 (Fotiou et al., 2015) and EPHB4 (Martin-Almedina et 
al., 2016), as well as CCBE1 (Hennekam Syndrome; Alders et al., 
2009; Connell et al., 2010) and genes associated with known lym-
phatic malformations, including FLT4 (Joukov et al., 1996; Achen 
et al., 1998; Gordon et al., 2013), FOXC2 (Fang et al., 2000; Sabine 
et al., 2012), and SOX18 (François et al., 2008). In all instances, 
with an average coverage of 10 × 117.5 in all regions, we found 
these genes to be normal. However, exome sequencing analysis 
led to the detection of a previously unreported homozygous vari-
ant in exon 9 of the CAL CRL gene: NM_005795.5: c.614_616del 
(p.Val205del), resulting in an in-frame deletion of amino acid va-
line 205 within the encoded protein, referred to as CLR (Fig. 1 C), 
hereafter referred to as V205del.
To date, this variant is not present in the Genome Aggrega-
tion Database, Exome Aggregation Consortium (ExAC), Exome 
Sequencing Project, or the 1000 Genomes browser. While the 
proband (III.4) and her unaffected daughter (IV.1) were hetero-
zygous for the mutation, the affected fetus (IV.3) was found to 
be homozygous (Fig. 1 C). The V205del variant was confirmed 
by Sanger sequencing and further testing was performed in 
other surviving adult members of the pedigree. Importantly, 
the proband’s husband (III.3), who is also a first-cousin, is het-
erozygous for the V205del variant (Fig. 1 C), thus corroborating 
homozygous inheritance in IV.3. The proband’s mother, II.3, also 
experienced multiple pregnancy losses, and is heterozygous for 
the CAL CRL V205del variant. Two of the proband’s sisters (III.6 
and III.10) consented to Sanger-based genetic testing and did not 
carry the V205del variant. Another sister (III.12), who has also 
experienced significant early pregnancy losses and is married to 
a first cousin from the same familial pedigree (Fig. 1 A), declined 
genetic testing.
Individuals III.4, III.3, II.3, and IV.1 were also heterozygous, 
and fetus IV.3 was homozygous, for a variant in the ASAH1 gene: 
c.1045C>G (p.Arg349Gly), which is present in the ExAC South 
Asian and European (non-Finnish) populations. Biallelic loss-
of-function mutations in ASAH1 are associated with Farber 
lipogranulomatosis (OMIM no. 228000), a lysosomal storage 
disorder that typically manifests during infancy, or in more se-
vere cases, with perinatal lethality or antenatal HF (Kattner et al., 
1997). However, we noted no clinical manifestation or symptoms 
indicative of this condition in IV.3 or in other nongenotyped fam-
ily members within this four-generation pedigree. Altogether, 
Figure 1. Familial pedigree, placental histology and sequencing traces of 
family with NIHF. (A) Whole exome sequencing identified mutations in subject 
IV.3 in hCAL CRL following the elimination of all previously implicated candidate 
genes. Parents, III.3 and III.4, and maternal grandmother were confirmed as hetero-
zygous carriers of the hCAL CRL(V205del) variant. Family history gives rise to two 
phenotypes dependent on haplotype: subfertility and nonimmune HF. (B) Placen-
tal histology from affected homozygous fetuses (IV.2 and IV.3) compared with a 
gestational-matched, normal placenta. The right column represents enlargements 
of boxed areas in the left column. Arrowheads indicate fetal vessels. In the case of 
the normal placenta, these vessels are completely filled with fetal erythrocytes and 
distributed both at the periphery and closer to the central villus core. In the case 
of the two affected placentas, the fetal vessels are more commonly found near the 
villus periphery, are compressed, and contain fewer erythrocytes. Arrows indicate 
presence of scattered Hofbauer cells. Asterisks indicate regions of severe edema 
within the chorionic villi of the affected placentas, a finding not seen in the normal 
placenta. (C) Whole exome sequencing traces for IV.3, III.4, and III.3 showing the 
amino acid residue valine 205 deletion (yellow). In individuals III.4 and III.3, the 
heterozygous allele (gray) is represented by the double peak.
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the family pedigree, genetic inheritance pattern and clinical phe-
notype support the identification of mutations in the CAL CRL 
gene as a novel causative pathway of human NIHF.
Genetic conservation of CAL CRL and residue V205
The human CAL CRL gene exhibits relatively few loss-of-function 
variants in the general population, as indicated by a high “prob-
ability of loss-of-function intolerance” (pLI) score (0.93) derived 
from the number of loss-of-function variants observed in the ExAC 
database compared with the expected number based on the size of 
the gene (16.9 Kb) (Lek et al., 2016). The V205del variant itself is 
absent from the Genome Aggregation Database, which contains 
genome-scale sequence data on nearly 140,000 individuals. In ad-
dition, this finding is highly consistent with the impaired subfer-
tility of the heterozygous female carriers (patients II.3 and III.4), 
suggesting that their low fecundity would be expected to contrib-
ute fewer loss-of-function variants to the population at large.
Consistently, we identified 67 conserved orthologues of the 
hCAL CRL gene and used multiple sequence alignment (Jalview 
and Clustal Omega; Sievers et al., 2011; McWilliam et al., 2013; Li et 
al., 2015) to establish the relative conservation of amino acid V205. 
We found that V205 is fully conserved across all species, except 
insects, being present in 62 of the 67 species represented. In four of 
the five species where the residue is not present (Lesser Hedgehog, 
Mouse Lemur, Sloth, and Wallaby), there is no equivalent residue, 
perhaps due to lack of sequencing coverage. A subset of the 62 
species alignment is represented in Fig. S1, and reveals stringent 
conservation of the V205 residue, even within a core of amino 
acids that displays significant sequence degeneracy among fishes.
Molecular modeling of Human Calcitonin Receptor-Like 
Receptor (hCLR) and hCLR(V205del)
To visualize the consequences of V205 deletion on the hCLR 
structure, we generated homology models of the hCLR (Fig. 2 A, 
blue) and hCLR(V205del) (Fig. 2 B, red) structures using SWI SS-
MOD EL (Arnold et al., 2006; Guex et al., 2009; Kiefer et al., 2009; 
Biasini et al., 2014), built on the structure of the corticotropin-re-
leasing factor receptor 1 as a GPCR family B member template 
(Hollenstein et al., 2013). Notably, deletion of V205 is predicted to 
cause loss of α-helical character in extracellular loop 1 (ECL1) and 
gain of an extra turn in the extracellular-facing helix of trans-
membrane 2 (TM2, green). These changes are accompanied by 
predicted loss or gain of hydrogen bonding. For example, His194 
loses the ability to interact with Gln215 and Thr196 undergoes a 
large shift in position. Asn200 and Asn201 gain and lose H-bond-
ing contacts, respectively, and the shift of Ala206 to Ala205 con-
tributes to the loss of α-helical character in ECL1. Finally, distal 
residues found in extracellular loop 2 (ECL2), Tyr277, and Ser285 
lose the ability to interact. These changes in residues in ECL1 are 
predicted to interfere with ligand binding in the receptor’s al-
losteric site resulting in a loss of potency. Importantly, previous 
alanine mutagenesis studies have shown that many of these af-
fected residues are important for receptor oligomerization with 
RAMPs and/or ligand binding (Barwell et al., 2011, 2012; Woolley 
and Conner, 2013; Watkins et al., 2016).
Therefore, we next developed dynamic molecular modeling 
of wild-type hCLR (Fig. 2 C) or hCLR(V205del) (Fig. 2 D) in com-
plex with hRAMP2 (yellow), which forms a functional receptor 
for hAM ligand (purple), using ROS ETTA (Barth et al., 2007) and 
MOD ELL ER (Šali and Blundell, 1993). The hCLR(V205del) com-
plex reveals a shortened distance between hRAMP2 helix 2 and 
the hAM binding site, ultimately distorting the binding pocket 
and displacing the N’ terminus of hRAMP2. Furthermore, the re-
positioning of hRAMP2 helix 2 causes a knock-on effect on hCL-
R(V205del), distorting TM1, TM6, and TM7, which are essential 
for presenting the receptor ligand binding pocket. Consistent 
with these molecular modeling predictions, replica exchange 
Monte Carlo (REMC) molecular dynamic simulations (Fig. 2 E 
and Video  1) confirmed a distorted hCLR(V205)–hRAMP1 
and –hRAMP2 interaction, with a significantly increased root 
mean square deviation for the hCGRP and hAM ligand docking 
(Fig. 2 F). Collectively, these structural modeling approaches pre-
dict that the mutant hCLR(V205del) protein is likely to display 
ineffective binding to both hRAMPs and ligands.
hCLR(V205del) abrogates cell signaling and RAMP-mediated, 
cell surface receptor expression
To directly test the signaling and receptor oligomerization 
competency of hCLR(V205del), we developed and used several 
orthogonal cell-based assays. First, using a bioluminescence res-
onance energy transfer (BRET)–based cAMP biosensor (Barak et 
al., 2008; Salahpour et al., 2012) we found that dose-dependent 
stimulation with the cognate peptide ligand, AM, robustly stim-
ulated cAMP production in hCLR: hRAMP2 -expressing HEK293T 
cells with maximal efficacy and nanomolar potency (Half maxi-
mal effective concentration, EC50 = 1.434 nM), as expected based 
on previous studies (Hay et al., 2003; Kuwasako et al., 2011; 
Fig. 3 A). However, the mutant hCLR(V205del) receptor exhib-
ited a reduction in cAMP production represented by the statisti-
cally significant loss of potency (EC50 = 12.13 nM; Fig. 3 A). This 
loss of signaling by the hCLR(V205del) receptor implies that the 
V205 residue is critical for either ligand-mediated receptor acti-
vation, or for proper receptor cell surface localization, or both.
Next, to distinguish between these possibilities, we adapted 
an infrared fluorogen activating protein (IRF AP) assay (Fig. S2, 
A and B; Szent-Gyorgyi et al., 2008; Fisher et al., 2014; Snyder 
et al., 2015, 2017) to screen for cellular cotranslocation of hCLR–
hRAMP heterodimer complexes to the cell surface, exploiting the 
fact that the forward trafficking of either hCLR or hRAMPs from 
the Golgi to the plasma membrane are mutually interdependent 
(McLatchie et al., 1998; Hay et al., 2006). As expected, the inter-
action of hCLR: FAP -hRAMP2 was robustly detected at 375 ng 
(Fig. 3 B, column 3). Conversely, the hCLR(V205del) variant ex-
hibited diminished levels of chaperone ability for FAP-hRAMP2, 
resulting in a statistically significant decrease of FAP signal de-
tected (Fig. 3 B, column 4). The intensity of pcDNA3.1 (column 
2) or the non-RAMP interacting GPCR, β2-adrenergic receptor 
(column 1), are shown as background controls.
Confocal microscopy of HEK293T cells expressing fluo-
rescently or epitope-tagged versions of the proteins corrobo-
rated these findings. In brief, cells were transfected to express 
3xHA-hRAMP2 protein (cyan) in the presence of Myc-hCLR or 
Myc-hCLR(V205del) (red) and hCLR-YFP or hCLR(V205del)-YFP 
(green) to evaluate the subcellular localization of individual 
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oligomer complexes (Fig. 3 C). In the 3xHA-RAMP2: Myc -hCLR: 
hCLR -YFP cotransfection, cells displayed robust colocalization 
of all three wild-type proteins at the plasma membrane, as in-
dicated by the yellow-merged staining (top row, right column). 
However, the hCLR(V205del)-YFP variant shows reduced lev-
els at the plasma membrane and remains largely intracellular 
(middle row, green). Importantly, under this condition, which 
mimics the phenotypic condition of individuals who are hetero-
zygous for the hCLR(V205del) variant, the expression of the mu-
tant hCLR(V205del) receptor does not invoke dominant negative 
effects on the forward trafficking of the wild-type hRAMP2 and 
hCLR to the plasma membrane (middle row, right column, white 
merge). Finally, none of the proteins traffic to the plasma mem-
brane when both Myc-hCLR(V205del) and hCLR(V205del)-YFP 
are coexpressed with 3xHA-hRAMP2 (bottom row).
hCLR(V205del) fails to form oligomers with hRAMPs
Since the effective signaling and plasma membrane localization 
of hCLR is fully dependent on RAMP protein interaction, we rea-
soned that the impaired functions of the hCLR(V205del) variant in 
the above assays might be caused principally by its inability to in-
teract with RAMPs. To test this hypothesis, we used two different 
Figure 2. Predicted structural changes and 
molecular dynamic modeling of wild-type and 
mutant hCLR and hCLR: RAMP2 complexes. (A 
and B) Predicted structural conformations of the 
hCLR and hCLR(V205del) by homology model-
ing using SWI SS-MOD EL. Cartoon views of the 
receptors predict structural changes centered on 
the site of mutation in extra cellular loop 1 (green). 
Inset shows predicted interactions involving 
side-chains and key residues are labeled to high-
light changes in hydrogen bonding (H194/194, 
N200/200, N201/201, Q216/215, Y278/277, and 
S285/284), large residue positional changes 
(T196), and the site of deletion (V205 and A205). 
(C and D) Snap-shots of CLR–RAMP2–AM com-
plexes after replica Monte Carlo simulations with 
either wild-type (C) or V205del (D) CLR. (E) Over-
lay of the RAMP/ECL1 interface of wild-type CLR–
RAMP2–AM (blue) and CLR(V205del)–RAMP2–
AM (red) complexes after REMC simulations. (F) 
Changes in root mean square deviation (RSMD) 
of wild-type and V205del CLR in complex with 
both RAMP1 and CGRP or RAMP2 and AM during 
REMC simulations.
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assays for protein–protein interaction. First, using BRET assays, 
we consistently observed robust and characteristic rectangular 
hyperbola saturation isotherms with wild-type hCLR-rLuc and 
hRAMP2-YFP, with a Bmax of 1.03, and a disassociation constant 
of Kd= 0.83 (Fig. 4 A, top). On the other hand, the hCLR(V205del) 
mutant resulted in a reduction of BRET signal indicated by a Bmax 
of 0.68, but interacted with a similar disassociation constant of Kd 
= 0.42 (Fig. 4 A, bottom). The biggest difference between the two 
saturation experiments was in the R2 or goodness of fit, where 
hCLR exhibited a 0.97 R2 and hCLR(V205) exhibited a 0.60 R2. 
Second, we used in situ proximity ligation assay (PLA; Chauhan 
et al., 2015), which detects protein–protein interactions at single 
molecule resolution within living cells. HEK293T cells transiently 
cotransfected with hCLR and hRAMP2 exhibited markedly robust 
PLA signal (207.5 ± 24.0 signals/cell), whereas cells coexpress-
ing the hCLR(V205del) variant showed a complete abatement of 
PLA signal (1.4 ± 0.8 signals/cell; Fig. 4 B). Collectively, these data 
demonstrate that V205 in hCLR is a critical residue for the for-
mation of the hCLR: hRAMP2 heterodimer, which is furthermore 
required for its normal subcellular localization and signaling.
Lymphatic Calcrl is essential for murine survival and lymphatic 
vascular development
CLR is a broadly expressed receptor with abundant expression in 
cardiovascular tissues and the peripheral nervous system. Simi-
lar to the family case report, global deletion of the Calcrl in mice 
results in mid-gestation embryonic lethality with profound inter-
stitial edema due to arrested lymphangiogenesis, an HF pheno-
type that is fully recapitulated in both Adm−/− and Ramp2−/− mice 
(Caron and Smithies, 2001; Dackor et al., 2006; Fritz-Six et al., 
2008; Kechele et al., 2016). In addition, we found that placentas 
from Calcrl−/− fetuses also exhibited marked interstitial edema 
within the labyrinth and enlarged junctional zone (Fig. 5 A), re-
flecting the pathology observed in the human condition.
Therefore, to gain insights into the functional consequences 
of lymphatic endothelial Calcrl loss during development, we 
generated lymphatic-specific Calcrl null animals using two in-
dependent Cre-driver lines: constitutively expressed, Lyve1-Cre 
(Pham et al., 2010), and the inducible Prox1-CreERT2 (Srinivasan 
et al., 2007). All Calcrlfl/fl;Lyve1-Cre animals died in late gesta-
tion (embryonic day 16.5 [E16.5]–17.5) with profound interstitial 
Figure 3. hCLR (V205del) exhibits impaired 
signaling and plasma membrane localization. 
(A) Detection of cAMP production with the EPAC 
biosensor after 45 min of AM stimulation of hCLR: 
hRAMP2 or hCLR(V205del):hRAMP2. n = 5 inde-
pendent experiments, in duplicate. (B) Infrared 
24-well plate imaging of transiently transfected 
HEK293T cells with MarsCy1(FAP)-tagged 
hRAMP2. Cells transfected with 375 ng of 
pcDNA3.1, hβ2ADR, hCLR, and hCLR (V205del) 
were cotransfected with FAP-tagged RAMP2 and 
cells were stained with the MarsCy1 and mem-
brane impermeant fluorogen SCi1. Compare cell 
surface expression to the pcDNA negative con-
trol. SCi1 stained cells were scanned at 700 nm 
(red, SCi1). n = 5 independent experiments, in 
duplicate. (C) Confocal microscopy of HEK293T 
cells expressing HA-hRAMP2 (cyan), Myc-hCLR 
(red), and hCLR-YFP (green). The top row shows 
the colocalization of all three wild-type proteins 
at the plasma membrane resulting in yellow-cyan 
color. The middle row shows the changes in 
protein distribution with coexpression of hCLR 
(V205)-YFP protein: wild-type HA-RAMP2 and 
Myc-hCLR colocalize to the plasma membrane 
(white merge), while the distribution of the 
hCLR (V205)-YFP protein (green) remains largely 
intracellular. The bottom row shows complete 
absence of all three proteins at the plasma 
membrane when both mutant forms of the hCL-
R(V205) receptor are expressed. Far right column 
shows the boxed regions at higher magnification. 
n = 2 independent experiments, with analysis of 
>50 cells per condition. Bar, 10 µm. **, P < 0.01; 
****, P < 0.0001.
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edema (Fig. 5 B). Similarly, tamoxifen injection of pregnant Cal-
crlfl/fl dams mated with Calcrlfl/fl;Prox1-CreERT2 males resulted 
in excision of the Calcrl gene and mid-gestation lethality with 
HF between E14.5 and 16.5 of Calcrlfl/fl;Prox1-CreERT2 embryos 
(Fig. 5 C; Fig. S3, A–D). Morphometric analysis of the developing 
jugular lymph vessels of Calcrlfl/fl;Prox1-CreERT2 embryos re-
vealed subcutaneous edema and significantly smaller lymphatic 
vessels (Fig. 6, A and B) that were developmentally arrested, as 
indicated by a >50% reduction in Ki67-positive lymphatic en-
dothelial cells within the jugular lymph sacs (Fig.  6, C and D) 
compared with littermate Calcrlfl/fl embryos. Analysis of dermal 
lymphatic vessels within the embryonic skin of Calcrlfl/fl;Prox1-
CreERT2 embryos also revealed the presence of developmentally 
arrested lymphatic capillaries that appeared significantly dilated 
and malformed within the environment of subcutaneous edema 
compared with the dermal lymphatic capillaries of normal Cal-
crlfl/fl embryos (Fig. 6, E–H).
Since abnormal lymphovenous valve formation during de-
velopment has recently been linked to GLD and NIHF in both 
mice and humans (Martin-Almedina et al., 2016), we carefully 
examined the lymphovenous valves of Calcrlfl/fl;Prox1-CreERT2 
embryos and observed normal structural morphology, appro-
priate compartmentalization of blood cells from lymph and 
high levels of Prox1 and Lyve1 staining (Fig. S4). Moreover, 
because Prox1 is expressed in myocardial cells and global loss 
of Calcrl results in reduced myocardial proliferation in mice 
(Dackor et al., 2006), we carefully evaluated the structure and 
development of the hearts of Calcrlfl/fl;Prox1-CreERT2 embryos 
and found them comparable in size and structure to wild-type 
littermates (Fig. S5).
Collectively, these results establish that loss of functional Cal-
crl within the lymphatic vasculature causes a mid-gestational 
proliferative arrest in lymphangiogenesis resulting in profound 
HF with associated placental edema, which are phenotypes en-
tirely consistent with the clinical presentation of NIHF in hu-
mans with the homozygous hCLR(V205del) variant.
Loss of RAMP2-mediated CLR signaling in mice recapitulates 
the hCLR(V205del) haplotype
CLR serves as the receptor for both AM and CGRP ligands, de-
pending on which RAMP the receptor is heterodimerized with. 
Thus, patients with the hCLR(V205del) variant are likely to be 
Figure 4. hCLR(V205del) does not interact with RAMPs. (A) Representative saturation isotherms from BRET assays of transiently transfected HEK293T 
cells with hCLR (top graph) or hCLR(V205) (bottom graph; fused to renilla luciferase) and increasing amounts of hRAMP2 (fused to eYFP). Experiments were 
performed at least three times and a representative experiment is shown. (B) PLA in transiently transfected HEK293T cells. Red indicates positive PLA signal, 
blue is nuclear DAPI stain, green is plasma membrane β-catenin. Negative controls included no transfection of hRAMP2. Graph depicts quantitation of signal, 
with asterisks denoting significant differences compared with control; ***, P < 0.001. n = 2 independent experiments, in duplicate, with 20 cells quantitated 
per condition. Bar, 10 µm.
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functionally deficient for both AM/RAMP2/3-mediated and 
CGRP/RAMP1-mediated signaling. We have previously demon-
strated that Ramp1 and Ramp3 null mice survive to adulthood 
with little to no overt phenotypes, consistent with a lack of 
overt phenotypes in mice deficit for CGRP (Dackor et al., 2007). 
Therefore, to more carefully parse the relative contributions of 
RAMP2-mediated signaling, we characterized the phenotypes of 
a unique Ramp2 transgenic line in which endothelial restoration 
of Ramp2 using a vascular endothelial-specific promoter to 
drive a Ramp2 transgene (Tg) is sufficient to partially rescue the 
edematous phenotype and embryonic lethality of Ramp2−/− mice 
(Kechele et al., 2016). Similar to the previously reported Ramp2+/− 
subfertility phenotype (Kadmiel et al., 2011), Ramp2−/−-Tg dams 
undergo implantation and maintain pregnancy to term, but 
they have significantly smaller litter sizes than Ramp2+/+-Tg or 
Ramp2+/−-Tg females (Fig.  7 A), further supporting the obser-
vation that haploinsufficiency for CLR-RAMP2 signaling in fe-
males, both in mice and in humans, is associated with subfertility 
(Kadmiel et al., 2011; Li et al., 2013). While Ramp2−/−-Tg pups 
were born at nearly Mendelian ratios (Fig. 7 B), ∼60–70% died 
perinatally with marked fluid accumulation, small focal hemor-
rhages in the skin, and HF (Fig. 7, C and D), likely due to the low 
level of VE-cadherin–mediated Ramp2 reconstitution in lym-
phatic vessels. Histology confirmed substantial amounts of inter-
stitial edema within a thickened subcutaneous layer of the skin 
in Ramp2−/−-Tg embryos compared with littermate Ramp2+/+-Tg 
controls (Fig. 7 E). Furthermore, the placentas from edematous 
Ramp2−/−-Tg embryos showed marked fluid-filled cavities within 
the labyrinth and junctional zones of the fetal placenta (Fig. 7, F 
and G). Collectively, the morphological phenotypes observed in 
the majority of Ramp2−/−-Tg embryos, including HF, thickened 
skin, placental edema, and embryonic demise are fully consistent 
with the clinical characteristics of NIHF in humans and further 
establishes the CLR–RAMP2–AM signaling axis as the molecular 
basis for NIHF and female subfertility observed in humans with 
a hCLR(V205del) variant.
Discussion
In summary, an in-frame deletion of a highly conserved valine 
reside in extracellular loop 1 of CLR, has been identified in six 
members of a consanguineous family, resulting in autosomal 
recessive GLD, with NIHF in homozygous carriers and female 
subfertility in heterozygous carriers. The mutation imparts 
structural changes within the receptor that diminishes its inter-
action with the requisite accessory chaperone protein RAMP, re-
sulting in reduction of receptor at the cell surface and significant 
impairment of ligand-mediated signaling. In animal models, we 
show that the expression of the CLR–RAMP2–AM signaling axis 
in lymphatic endothelial cells is both necessary and sufficient for 
mammalian survival and normal female reproductive function, 
providing a cellular and molecular foundation for the clinical 
manifestations observed in humans with the hCLR(V205del) 
variant. The impact and relevance of these findings can be ex-
trapolated to at least three different areas.
First, these findings provide, to our knowledge, the third case 
of genetically inherited NIHF associated with GLD, thereby in-
creasing the repertoire of candidate factors for genetic testing 
and screening beyond the very recently identified disease-asso-
ciated PIE ZO1 and EPHB4 genes. Moreover, based on deductions 
from animal model studies, as well as the extensive, four-gener-
ation pedigree, we also conclude that haploinsufficiency for the 
CLR–RAMP2–AM axis is associated with clinical subfertility in 
female carriers. Collectively, this work provides additional diag-
nostic criteria for causes of NIHF and female subfertility, as well 
as three additional genes for candidate genetic testing: CAL CRL, 
ADM, and RAMP2.
Second, the remarkable conservation of phenotype between 
the human patients and the genetic animal models provides com-
pelling evidence for the evolutionarily conserved functions of the 
AM–CLR–RAMP2 signaling axis in embryonic vascular develop-
ment and female fertility. In contrast, the hCLR(V205del) variant 
appeared to have little consequence on CGRP-mediated physiol-
ogy, which is further supported by the lack of overt phenotypic 
Figure 5. Placental edema, HF, and fetal demise in mice lacking Calcrl. 
(A) Placenta from E13.5 Calcrl+/+ and edematous Calcrl−/− littermates, reveal-
ing significant interstitial edema within an expanded junctional zone (jz). Yel-
low arrows highlight fluid filled spaces in the jz. (B) Representative images of 
E17.5 Calcrlfl/fl and Calcrlfl/fl/Lyve1-Cre littermates. Asterisks indicate edema. n 
= 5–7 animals in each group. (C) Representative images of E14.5 Calcrlfl/fl and 
Calcrlfl/fl; Prox1-CreERT2 littermates from tamoxifen treated dams. Asterisks 
indicate edema. n = 8–10 animals in each group. Bars, 2 mm.
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effects in either CGRPΑ−/−, CGRPΒ−/−, Ramp1−/−, or Ramp3−/− mice 
(Dackor et al., 2007). This may help explain why antibody-me-
diated CGRP antagonist therapies have recently shown tremen-
dous promise, with little side effects, in several large-scale phase 
III trials for the treatment of migraine (Goadsby et al., 2017; 
Silberstein et al., 2017).
Finally, using molecular dynamic modeling and biochemical 
approaches we have demonstrated the requisite functions im-
parted by a GPCR–RAMP interaction for the normal trafficking, 
signaling, and physiology of a family B GPCR. These findings 
are particularly timely, since the molecular crystallization of 
three family B GPCRs, CRF, GLP-1, and glucagon receptors, have 
recently been elucidated (Hollenstein et al., 2013; Song et al., 
2017; Zhang et al., 2017). Notably, Zhang et al. demonstrated 
that the ECL1 region of the glucagon receptor, which also in-
teracts with RAMPs (Weston et al., 2015), is critical for forming 
the peptide binding interface. Together, these findings demon-
strate that ECL1 is a functionally critical structure of family B 
GPCRs, and imparts physiological relevance to this motif in hu-
mans. Future cocrystallization of active-state family B GPCRs 
in oligomeric complex with RAMPs will likely reveal novel in-
sights into the structure–function relationships imparted by 
these protein–protein interactions. Indeed, while the current 
work was focused on the canonical RAMP-associated receptor, 
CLR, it is worth emphasizing that over a dozen GPCRs have 
been shown to interact and function through RAMPs, includ-
ing calcitonin (Armour et al., 1999), parathyroid hormone, and 
vasointestinal peptide receptors (Christopoulos et al., 2003) 
as well as other nonfamily B GPCRs such as GPR30 (Lenhart et 
al., 2013), glucagon (Weston et al., 2015), and calcium sensing 
receptors (Bouschet et al., 2005). Thus, the physiological impli-
cations of aberrant GPCR-RAMP oligomerization may be vastly 
underappreciated. Furthermore, these studies open potential 
avenues for the development of therapeutic pharmacological 
chaperones to enhance GPCR–RAMP interaction as a means to 
promote receptor trafficking, as has successfully been accom-
plished for other disease-causing plasma membrane protein 
variants such as V2 vasopressin receptor (Morello et al., 2000), 
CFTR (Drumm et al., 1991), and aquaporin-2 (Tamarappoo and 
Verkman, 1998).
Figure 6. Lymphatic deletion of Calcrl leads to 
developmentally arrested lymphatics, hypo-
plastic jugular lymph sacs, and dilated dermal 
lymphatic vessels. (A) Measurement of jugular 
lymph sac area in E14.5 Calcrlfl/fl and Calcrlfl/fl/
Prox1-CreERT2 embryos. Quantitative data are 
represented as mean and SEM for area. n = 6–7 
animals per group. (B) Representative images of 
H&E-stained sections of E14.5 Calcrlfl/fl and Calcrlfl/
fl/Prox1-CreERT2 embryos showing jugular lymph 
sac (JLS), jugular vein (JV), and severe edema (*). 
Bars, 100 µm. (C) Number of Ki67-positive cells 
per jugular lymph sac in Calcrlfl/fl and Calcrlfl/fl/
Prox1-CreERT2 embryos. Quantitative data are rep-
resented as mean and SEM for number of Ki67-pos-
itive cells. n = 6 animals per group. (D) Represen-
tative images of LYVE1 (green), PROX1 (red), and 
Ki67 (blue) stained sections of E14.5 Calcrlfl/fl and 
Calcrlfl/fl/Prox1-CreERT2 embryos showing prolifer-
ating cells in jugular lymph sac (JLS). Boxed regions 
are shown as magnified insets. Arrowheads high-
light Ki67-positive lymphatic endothelial cells. Bars, 
100 µm. (E) Dermal lymphatic vessel diameter of 
Calcrlfl/fl and Calcrlfl/fl/Prox1-CreERT2 embryos. n = 
3–5 animals per group. (F) Podoplanin (PDPN, red) 
stained dermal lymphatic vessels from E13.5 Cal-
crlfl/fl and Calcrlfl/fl/Prox1-CreERT2 embryos. White 
line highlights width of the lymphatic vessel. Bars, 
25 µm. (G) Quantification of phosphohistone H3 
(pHH3)–positive cells in E13.5 Calcrlfl/fl and Calcrlfl/
fl/Prox1-CreERT2 dermal lymphatic vessels. Data 
are represented as mean and SEM for number of 
pHH3-positive cells per branch. n = 3–5 animals 
per group. (H) Representative images of PDPN 
(red) and pHH3 (green) stained dermal lymphat-
ics of E13.5 Calcrlfl/fl and Calcrlfl/fl/Prox1-CreERT2 
embryos. Arrowheads indicate pHH3-positive 
cells. Bars, 1 µm. Quantitative data are represented 
as mean and SEM. In all panels, significance was 
determined by Student t test (tail = 2, type = 2) with 
*, P < 0.05; **, P < 0.005; ***, P < 0.0001.
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Materials and methods
Targeted capture and parallel sequencing
Genomic DNA was extracted from the fetal cord blood of fam-
ily member IV.3 and from blood samples of family members II.3, 
III.3, III.4, III.6, III.10, and IV.1. Whole-exome sequencing was 
performed on exon targets isolated from patient IV.3 by capture 
using nextSeq Exome sequencing Platform (Illumina) at Cento-
Gene and an end-to-end bioinformatics pipeline was applied. 
This included base calling, primary filtering of low quality reads, 
and probable artifacts and annotation of variants. For medical 
evaluation purposes, all disease causing variants reported in 
HGMD, in ClinVar (class 1 and 0), and all variants with minor 
allele frequencies of >1% in the ExAC database were considered. 
All variants that could possibly impair the protein sequence, 
i.e., disruption of conserved splice sites, missense, nonsense, 
read-throughs, or small insertion/deletion were prioritized. 
The percent coverage at 10× for patient IV.3 was 95.64%, while 
the coverage for the mother III.4 and father III.3 was 96.59% 
and 97.10%, respectively. The average fold coverage for patient 
IV.3 was 117.57%, while for the mother III.4 and father III.3 was 
133.36% and 140.96%, respectively.
Molecular modeling of hCLR, hCLR(V205del), and 
RAMP interaction
Two hCLR and hCLR(V205del) GPCR homology models were con-
structed. The hCLR and hCLR(V205del) sequences (UniProtKB: 
Q16602 and Q16602 with valine 205 deleted) were used as the 
targets. The GPCRs were aligned against human corticotropin-re-
leasing factor receptor 1 (PDB no. 4K5Y; Hollenstein et al., 2013) 
using SWI SS-MOD EL automated mode (Biasini et al., 2014). These 
models resulted in a Model-Template Range of 138–389 amino 
acids. The top homology models were chosen using the QME AN 
score (Benkert et al., 2009a,b, 2011). In brief, QME AN is a com-
posite scoring function for the estimation of the global and local 
model quality. It consists of four structural descriptors: the local 
geometry is analyzed by a torsion angle potential over three con-
secutive amino acids. Two pairwise distance-dependent potentials 
are used to assess all-atom and C-β interactions. A solvation po-
tential describes the burial status of the residues. Furthermore, 
the Corticotropin-releasing factor receptor 1 was use as the target 
GPCR for generation of the homology model because it is a mem-
ber of the secretin receptor family and the same subfamily, B1, as 
hCLR. Once the models were generated they were exported for 
use in PyMOL. In PyMOL, both GPCR structures were probed for 
changes in polar contacts involving side chains centered on the 
site of the valine 205 deletion (magenta). The labeled residues in-
dicate the changes in predicted hydrogen bonding, large positional 
changes, cysteine bonds, or the site of the amino acid deletion.
Homology models of hCLR were generated using the recently 
published cryo-electron microscopy structure of 5VAI and the 
x-ray crystallographic of 3N7P as described previously (Woolley 
et al., 2017). The position of the N-terminal region of hRAMP1 
was aided by superimposing the crystal structure of 4RWG to 
the homology model of hCLR. After which the hCLR component 
(leaving the RAMP region intact) was removed and the complex 
minimized using MOD ELL ER. The transmembrane component 
of hRAMP1 was generated using an in house script and docked 
Figure 7. Genetic loss of Ramp2 leads to subfertility, perinatal HF, and 
lethality. (A) Litter sizes from Ramp2+/− ntg males crossed with Ramp2+/+Tg, 
Ramp2+/−Tg, and Ramp2−/−Tg females. n = 8–12 litters per genotype. Significance 
was determined by one-way ANO VA with Tukey’s Multiple Comparison test. (B) 
Breeding results, both expected and observed Mendelian ratios from Ramp2+/− ntg 
male crossed to Ramp2−/−Tg female. n = 45 from 8 litters. (C and D) Representative 
images of P1 (C) and E18.5 Ramp2−/−Tg (D) mice compared with littermate controls. 
Bars, 5 mm. (E and F) Representative histological images of skin (E) and placenta 
(F) from E18.5 Ramp2+/+Tg and edematous Ramp2−/−Tg littermates. Double-sided 
arrow indicates subcutaneous edema. Bars, 500 µm. (G) Higher magnification of 
boxed regions from panel F. Yellow arrow points to fluid filled edematous regions. 
Small arrowheads indicate abnormally shaped trophoblast cells lining the chori-
onic plate. lb, labyrinth; cp, chorionic plate. Bars, 100 µm.
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into the hCLR + N’ terminal hRAMP model using GRA MM in 
low resolution helix docking mode. Each of the 10,000 docked 
positions of hRAMP1 TM against the hCLR-RAMP1 N’ terminal 
model was refined using ROS ETTA. The top 1% of the best scor-
ing structures were clustered using a cutoff of 2A. Three clusters 
emerged and the middle structure of each cluster was used to 
generate three complete homology models of the hCLR-hRAMP1 
complex. REMC simulations were used to refine each model (16 
temperatures spanning 300–500 K following a Boltzmann distri-
bution), after which the final structures were scored using ROS 
ETTA and the best structure was used for the subsequent study. 
The deletion of V205 was performed using MOD ELL ER. Parallel 
REMC simulations of the wild-type hCLR–hRAMP1 complex as 
well as the deletion were performed and compared. To access the 
research data supporting the molecular dynamic simulations in 
this publication, see Poyner and Simms, 2018.
Generation of hCLR and hRAMP2 expression constructs
The hCLR mammalian expression plasmid Myc-hCLR-phR-
LucN3 (hCLR-rLuc) were donated by the laboratory of M. Bou-
vier (Université de Montréal, Montreal, Canada) and used as the 
template for site-directed mutagenesis using the QuikChange 
II XL Site-Directed Mutagenesis kit (Agilent Genomics) to gen-
erate the hCLR(V205del) mutant. Mutagenesis primers were 
designed using QuikChange Primer Design Tool (Agilent Ge-
nomics). Myc-hCLR and Myc-hCLR(V205del) were further sub-
cloned into pcDNA3.1(+) to remove the rLuc moiety for additional 
experiments. The hRAMP2 mammalian expression plasmid 
hRAMP2/pcDNA3.1 was purchased from the cDNA Resource Cen-
ter (Bloomsburg University, Bloomsburg, PA). The hRAMP2 gene 
was subcloned into the pEYFP-N1 vector to generate hRAMP2-
eYFP. All constructs were verified by DNA sequencing.
BRET
HEK293T cells were maintained in standard conditions. Trans-
fections were performed using Lipofectamine 2000 Reagent 
(Thermo Fisher) following the manufacturer’s specifications. 
In brief, 96-well white, clear bottom plates (Corning) were 
coated with poly-d-lysine. 50,000 cells were seeded into each 
well and grown overnight in 37°C, 5% CO2. The next day, cells 
were transfected with a serial dilution of hRAMP2-eYFP DNA 
(15–0 µg) with a constant concentration of hCLR-rLuc or hCL-
R(V205del) to generate the saturation isotherm. On day 3, the 
media was aspirated and replaced with 90 µl 1× PBS and 10 µl 
of 10× coelenterazine, incubated for 10 min, and the plates were 
read on a Mithras LB 940 Multimode Microplate Reader (Ber-
thold Technologies).
cAMP EPAC biosensor assay
HEK293T cells were transfected using the calcium phosphate 
transfection protocol; see reference above. In brief, 10-cm dishes 
were seeded with four million cells and grown overnight in stan-
dard conditions. The next day, each dish was transfected with 
4 µg EPAC biosensor, 2.5 µg of hRAMP2, and 2.5 µg of either 
hCLR or hCLR(V205) or empty vector. After 18 h, cells are har-
vest and seeded at 100,000 cells per well into a white 96-well 
poly-d-lysine coated plate in phenol-free reduced serum DMEM 
(supplemented with 2% FBS, 1% Hepes, and 750 µl of Gentamicin; 
Sigma). On the day of the experiment, fresh AM stock was made 
at 1 mM, and a half-log dilution series was generated with a final 
concentration in the assay of 10 µM to 31.6 pM. Media was aspi-
rated from each well and replace with 80 µl of PBS and 10 µl of 
10× coelenterazine and incubated 10 min. Next, 10 µl of AM was 
added to each well and the plate was incubated for 45 min in the 
dark at room temperature. All assays were read on a Mithras LB 
940 Multimode Microplate Reader.
Fluorogen activating protein (FAP) assay
Fluorogen was obtained from the laboratory of A. Waggoner 
(Carnegie Mellon University Technology Center of Networks 
and Pathways, Pittsburgh, PA). Gateway cloning technology 
(Thermo Fisher) was use to generate the FAP-RAMP2 fusion pro-
tein. To investigate the hRAMP2 chaperone activity all experi-
ments were performed using poly-d-lysine–coated, 24-well clear 
plates. 175,000 HEK293T cells were seeded into each well and 
grown overnight. The following day, each well was transfected 
by calcium phosphate transfection with 250 ng of FAP-hRAMP2 
and 375 ng of hCLR, hCLR(V205del), β2ADR, or pcDNA3.1. Cells 
were grown for 18 h in transfection media and assayed for FAP 
expression. Media was aspirated and replaced with 250  µl of 
room-temperature PBS with a 1:6,000 dilution of fluorogen SCi1 
and incubated for 10 min. Next, 250 µl of PBS without fluorogen 
and each plate was read on an Odyssey CLx imaging system (Li-
COR Biosciences).
PLA
HEK293T cells were seeded into poly-d-lysine coated MatTek 
plates and transfected with hCLR or hCLR(V205) or hβ2 adrener-
gic receptor and hRAMP2 or pcDNA3.1 using calcium phosphate. 
At 24 h after transfection, cells were washed with room tempera-
ture PBS and fixed onto plates with fresh 4% paraformaldehyde 
in PBS. Cells were then probed by PLA using the Duolink In Situ 
Red kit Goat/Rabbit (Sigma) in a humidity chamber according to 
manufacturer’s specifications. In brief, cells were blocked with 
4% BSA in PBS, incubated with appropriate primary antibodies 
and then incubated with PLA probes, anti-Goat and anti-Rabbit 
secondary antibodies conjugated to unique oligonucleotides. 
Each sample was treated with a ligation solution which allows 
the oligo pairs in close proximity for form a close loop. Next, roll-
ing-circle amplification was initiated by the addition of an am-
plification solution that contains polymerase and fluorescently 
labeled oligonucleotides, which produces discrete fluorescent 
dots. After the PLA protocol, cells were counterstained with a 
mouse anti–β-catenin primary antibody (610153; BD Biosciences) 
and donkey anti-mouse Alexa Fluor 488 secondary antibody to 
visualize the plasma membrane and Hoechst to mark the nu-
cleus. Cells were analyzed by confocal laser scanning microscopy. 
A minimum of 25 cells were imaged for analysis, and each red 
dot was scored as a single interaction using BlobFinder software 
(Allalou and Wählby, 2009).
Animal studies
All animal procedures were approved by the University of North 
Carolina Chapel Hill Institutional Animal Care and Use Committee.
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Calcrlfl/fl/Prox1-CreERT2 mice were generated by crossing Cal-
crlfl/fl mice that were on a N7-10 on C57BL/6 background to Prox1-
CreERT2 NMRI line (Srinivasan et al., 2007) a gift from G. Oliver 
(Northwestern University, Chicago, IL). Cre-mediated recombi-
nation was induced by administering tamoxifen (Tam; T5648; 
Sigma) dissolved in corn oil and ethanol to pregnant female mice 
aged 4–6 mo for three consecutive days from E8.5 to10.5 at a dose 
of 5 mg/40 g intraperitoneally and their embryos harvested at 
various stages during gestation. Calcrlfl/fl/Lyve1-Cre mice were 
generated by crossing the aforementioned Calcrlfl/fl line to Lyve-1 
Cre+ line obtained from Jackson Lab (JAX stock 012601; Pham et 
al., 2010). Ramp2+/− were crossed to Tg(Cdh5-Ramp2)1Car hemi-
zygous mice and maintained on an isogenic C57BL/6 background 
as previously reported (Dackor et al., 2007; Kechele et al., 2016). 
Ramp2+/− males were crossed to Ramp2+/−; Tg(Cdh5-Ramp2) 
dames, and viable progeny were harvested during late gestation. 
Littermate controls were used for all animal studies. Primers 
used for genotyping were Calcrl wild-type allele, 5′-GCG GAG CAT 
ATT CAA TCA CAAG-3′ and 5′-GAA ATG TGC TGT ATG TTC AAGC-3′; 
Calcrl floxed allele, 5′GCG GAG CAT ATT CAA TCA CAAG-3′ and 5′-
GAC GAG TTC TTC TGA GGG GA-3′; Prox1-CreERT2 allele, 5′-CGA 
GCT CTT TCT CTC TAC AGT TCA ACA-3′ and 5′-GGC CAG TAA CGT 
TAG GGA GAGG-3′; Lyve-1 Cre+ allele, 5′-TGC CAC CTG AAG TCT 
CTC CT-3′ and 5′-TGA GCC ACA GAA GGG TTA GG-3′ and 5′-GAG GAT 
GGG GAC TGA AAC TG-3′; excised Calcrl allele, 5′GCG GAG CAT ATT 
CAA TCA CAAG-3′ and 5′-GAA TAA GTT GAG CTG GGC AG-3′; Ramp2 
wild-type allele, 5′-FAA GTC AGG CAG TCA GGG TTG-3′ and 5′-TCT 
GTC TGG ATG CTG CCT TGC-3′; Ramp2 null allele, 5′-GAC GAG TTC 
TTC TGA GGG GA-3′ and 5′-TCT GTC TGG ATG CTG CCT TGC-3′; and 
the Tg(Cdh5-Ramp2) allele, 5′-GAC TAC AAA GAC GAT GAC GAC 
AAGC-3′ and 5′-GTC CAT GCA ACT CTT GTA CTC ATA CC-3′.
Tissue preparation, histology, and immunofluorescence
For cellular staining, 500,000 HEK293T cells were seeded into 
35-mm MatTek glass-bottom dishes coated with poly-d-ly-
sine and grown overnight. Cells were transfected with 150 ng 
of hRAMP2 and 150 ng of either hCLR or hCLR(V205del) or 
pcDNA3.1 using calcium phosphate. The following day, cells were 
washed with room temperature PBS and fixed onto plates with 
fresh 4% paraformaldehyde in PBS.
Viable mouse embryos were collected and fixed in 4% para-
formaldehyde in PBS for 24 h at 4°C. Whole mount back skin was 
collected and stained as described in Li and Mukouyama (2011). In 
brief, limb skins were peeled after dehydrating in 100% MeOH fol-
lowed by rehydration and antibody staining. Embryos were par-
affin embedded, transversely sectioned, and stained with either 
H&E or Masson’s Trichrome according to standard protocols. Tis-
sues and cells were washed with PBS and permeabilized with 0.1% 
Triton X-100 in PBS, washed, and blocked for 1 h at room tempera-
ture with 5% normal donkey serum or 4% BSA in PBS. Samples 
were probed with primary antibodies directed toward rabbit an-
ti-LYVE1 (1:250; Fitzgerald), rat anti-Ki67 (1:150; VP-RM04; Vec-
tor Labs), rabbit anti-pHH3 (1:200; 6-570; Cell Signaling) human 
anti-Prox1 (1:100; AF2727; R&D Systems), Syrian hamster-an-
ti-podoplanin (1:100; DSHB8.1.1), rat anti-PEC AM (1:100; 550274; 
BD PharMingen), rabbit anti-myc (1:500; ab9106; Abcam), and 
goat anti-HA (1:250; ab9134; Abcam) overnight at 4°C. Samples 
were washed with 0.1% Triton X-100 in PBS and probed with don-
key anti-rabbit Cy2 (1:200; Jackson ImmunoResearch) and don-
key anti-goat Cy3 (1:400; Jackson ImmunoResearch) conjugated 
secondary antibodies for 1.5 h at room temperature in the dark. 
Bisbenzimide H 33258 (Hoechst; 1:1000; B1155; Sigma) was used 
to label nuclei. Samples were washed with PBS and imaged.
Microscopy and image analysis
Fixed whole mount mouse embryos were imaged using a 
MZ16FA dissecting stereoscope (Leica) with a QImaging Micro-
publisher 5.0 color camera using QCapture imaging software 
(QImaging). H&E- and Masson’s Trichrome–stained tissues were 
imaged using on a Dialux 20 microscope (Leitz) using similar 
camera and software. Fluorescently stained mouse tissue was 
imaged using either a Nikon E800 fluorescence microscope with 
a Hamamatsu Orca camera and MetaMorph software (Molecu-
lar Devices Corporation) or a Zeiss LSM 700 confocal laser-scan-
ning microscope and ZEN 2011 software. Stained HEK293T cells 
were visualized with a Zeiss 880 scanning confocal microscope 
mounted on an Inverted Axio Observer Z1 equipped with Defi-
nite Focus. All images were psuedocolored and analyzed using 
ImageJ (National Institutes of Health); Fiji and R-values were 
calculated using Coloc2 (Schindelin et al., 2012).
Real-time qPCR
Mouse embryonic tissue was collected and stored in RNAlater 
(AM7021; Ambion). RNA was extracted and converted to cDNA 
as per Davis et al. (2017). HEK293T cells were seeded at 2.5 mil-
lion cells per 10-cm dish and grown overnight in standard con-
ditions (DMEM supplemented with 10% FBS, 1% Hepes, and 
750  µl of Gentamicin; Sigma). Transfections were performed 
using calcium phosphate transfection as outlined by Kingston 
et al. (Kingston et al., 2003a,b). In brief, 1  ml of transfection 
mixture containing 10 µg of Myc-hCLR, Myc-hCLR(V205del), or 
pcDNA3.1 was added to each dish and grown overnight. RNA from 
tissues and cells was harvested using TRIzol reagent (15596026; 
Ambion) followed by DNase (M6101; Promega) treatment, and 
cDNA was prepared using iScript (170-8890; BioRad).
Real time-qPCR was performed using single-tube Assay 
on Demand (Thermo Fisher Scientific/Applied Biosys-
tems) for human CAL CRL (Hs00907738_m1), mouse Calcrl 
(Mm00516986_m1), human GAP DH (4310884E), and mouse 
Gapdh (Mm99999915_g1) on a StepOnePlus Real-Time PCR 
system (Applied Biosystems). Comparative ΔΔCT method was 
used to analyze relative gene expression normalized to GAP DH 
housekeeping control.
Statistical analysis
Statistical analysis was determined using GraphPad 5.0, and the 
data are represented as the mean ± SEM. Significant differences 
were determined by either Student’s t test or one-way ANO VA 
with Tukey’s Multiple Comparison test and represented as *, P < 
0.05; **, P < 0.01; and ***, P < 0.001.
Online supplemental material
Fig. S1 shows conservation of hCLR Valine205 residue across 
species. Fig. S2 shows the establishment and optimization of the 
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IRF AP assay. Fig. S3 shows spatiotemporal deletion of Calcrl in 
developing lymphatic vessels. Fig. S4 shows that lymphovenous 
valves develop normally in Calcrlfl/fl;Prox1-CreERT2 embryos. Fig. 
S5 shows that heart structure appears normal in Calcrlfl/fl;Prox1-
CreERT2 embryos. Video 1 shows the dynamics of CLR–RAMP2–
AM complexes (hCLR(V205del) and wild-type hCLR) following 
REMC simulations at 300 K.
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